title: Glucagon induces suppression of ATP-sensitive K+ channel activity through a Ca2+/calmodulin-dependent pathway in mouse pancreatic beta-cells.
abstract: Glucagon is known to increase intracellular cAMP levels and enhance glucose-induced electrical activity and insulin secretion in pancreatic beta-cell perfused with Krebs-Ringer bicarbonate solution. The present experiments were aimed at evaluation of the hypothesis that changes in beta-cells ATP-sensitive K+ (K(ATP)) channel activity are involved in the glucagon-induced enhancement of electrical activity. Channel activity was recorded using the cell-attached configuration of the patch-clamp technique. Addition of glucagon (2.9 x 10(-7) m) in the presence of 11.1 mm glucose caused closure of K(ATP) channels followed by an increase in the frequency of biphasic current transients (action currents) due to action potential generation in the cell. Three calmodulin-antagonists (W-7, chlorpromazine, and trifluoperazine) restored with similar efficacy K(ATP) channel activity in cells being exposed to glucagon. At 2.8 mm glucose, glucagon did not affect K(ATP) channel activity until Ca2+ was released from Nitr-5 by flash photolysis, at which point channel activity was transiently suppressed. Similar effects were seen when db-cAMP was used instead of glucagon. These results support the view that glucagon and other cAMP-generating agonists enhance glucose-induced beta-cell electrical activity through a Ca2+/calmodulin dependent-closure of K(ATP) channels.
authors.affiliation: Department of Physiology, Shiga University of Medical Science Ohtsu, 520-21 Japan.
authors.forename: L P
authors.initials: LP
authors.lastname: He
authors.forename: D
authors.initials: D
authors.lastname: Mears
authors.forename: I
authors.initials: I
authors.lastname: Atwater
authors.forename: H
authors.initials: H
authors.lastname: Kitasato
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000255:Adenosine Triphosphate / Q000502:physiology*; D000818:Animals; D003994:Bucladesine / Q000494:pharmacology; D020013:Calcium Signaling / Q000187:drug effects*; D002147:Calmodulin / Q000037:antagonists & inhibitors / Q000502:physiology*; D002746:Chlorpromazine / Q000494:pharmacology; D005934:Glucagon / Q000494:pharmacology*; D005947:Glucose / Q000378:metabolism; D015640:Ion Channel Gating / Q000187:drug effects*; D017136:Ion Transport / Q000187:drug effects*; D007515:Islets of Langerhans / Q000187:drug effects* / Q000378:metabolism; D008564:Membrane Potentials / Q000187:drug effects; D051379:Mice; D008813:Mice, Inbred ICR; D018408:Patch-Clamp Techniques; D010782:Photolysis; D011188:Potassium / Q000378:metabolism*; D026902:Potassium Channel Blockers; D015221:Potassium Channels / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology; D014268:Trifluoperazine / Q000494:pharmacology
chemical_list: D002147:Calmodulin; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D013449:Sulfonamides; D014268:Trifluoperazine; D003994:Bucladesine; C017967:W 7; D000255:Adenosine Triphosphate; D005934:Glucagon; D005947:Glucose; D011188:Potassium; D002746:Chlorpromazine